التفاصيل البيبلوغرافية
| العنوان: |
Argus® II Retinal Prosthesis System Treatment: Saudi Arabia Experience, King Khaled Eye Specialist Hospital (KKESH). |
| المؤلفون: |
S., Al Rashaed, T., Hamadi, E., Kahtani, H., Dhibi, A., Towerki, F., Arevalo |
| المصدر: |
Ophthalmic Research; 2017 Supplement, Vol. 58, p6-6, 1/3p |
| مصطلحات موضوعية: |
RETINA transplants, RETINITIS pigmentosa, SURGERY safety measures, BLINDNESS, THERAPEUTICS |
| مصطلحات جغرافية: |
SAUDI Arabia |
| مستخلص: |
Introduction/Background: The Argus II Retinal Prosthesis System (Second Sight Medical Products, Inc, Sylmar, CA) was developed to restore some vision to patients blind as a result of retinitis pigmentosa (RP) or outer retinal degeneration. Methods: 10 Retinitis Pigmentosa patients have been implanted at the KKESH: 3 female and 7 male, average age 41.3 years, 6 OD and 4 OS implanted eyes. Mean duration was 2.1 years. The primary outcome measures were safety (the number, seriousness, and relatedness of adverse events) and visual function, as measured by 2 computer-based, objective tests. Results: All 10 patients remained implanted with functioning Argus II Systems at 4 years after implantation. Only 1 additional serious adverse event (suture exposure over the coil suture tab and over the inferior case suture tab) was experienced 2-years postimplant. Patients performed significantly better with the Argus II on than off on all visual function tests and functional vision tasks (Square Localization: mean error across the population of tested patients was 8.83 cm [SD 0.94 cm] while it was 16.11 cm [SD 1.56 cm] with the system "off"; Direction of Motion: mean error across the population of tested patients was 81.32 degrees [SD 6.22 degrees] while it was 90.60 degrees [SD 5.90 degrees] with the system "off."). This demonstrates the clinical benefit that Argus II patients implanted in our center receive, and it translates into real life improvements for the majority of patients. Conclusions: The 10 KKESH Argus II patients demonstrate a safety profile that is at up to 4 years post-implantation markedly better than that observed in the developmental phase of Argus II. The results confirm previous reports on the ability of the Argus II prosthesis to provide visual function and functional vision over several years of chronic device use. [ABSTRACT FROM AUTHOR] |
|
Copyright of Ophthalmic Research is the property of Karger AG and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
